Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
1. Phase 3 EV-302 trial data shows improved survival for enfortumab vedotin plus pembrolizumab. 2. Overall survival is 33.8 months compared to 15.9 months with chemotherapy. 3. Combination therapy reduced death risk by 49% versus chemotherapy. 4. Further data supports this treatment as standard care for advanced urothelial cancer. 5. Findings could enhance Pfizer's oncology market position.